Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SenoMune-0257
- Development stage
- Preclinical
- Lead developer
- Immorta Bio
- Modality
- Peptides
01
Overview
SenoMune-0257 is an AI-designed synthetic nine-amino-acid peptide immunotherapy developed by Immorta Bio. It is designed to restore the immune system's natural ability to recognize and eliminate senescent cells ('zombie cells') by stimulating cytotoxic T cells to selectively target and destroy them while sparing healthy cells. Developed using artificial intelligence and building on Immorta Bio's earlier SenoVax research platform, SenoMune-0257 is intended to treat diseases associated with cellular senescence and aging, including cancer and accelerated aging conditions. As of October 2026, the candidate has completed planned preclinical studies and is preparing to enter clinical development, with initial human evaluation anticipated before the end of 2026.
- Other names
- SenoMune 0257SenoMune0257SenoMune-0257SenoMune™-0257
Beyond the preview
Go deeper on SenoMune-0257.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SenoMune-0257.